Price
$186.65+10.01%Social Signal Score
Analyst Ratings
41 analysts52-week range
- Last close
- $186.65
- Off 52w high
- -10.9%
- 200-day average
- $180.04
- vs 200-day
- +3.7%
Revenue
$15.99B+186.36%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Pascal Claude Roland Soriot
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 96,100
- Beta
- 0.21
- Country
- GB
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 3.48
Financials
Revenue
$15.99B+186.4%Net Income
$3.08B+67.0%EBITDA
$5.90B+89.4%Free Cash Flow
$3.99B+202.5%EPS (diluted)
$1.97+35.9%Shares Outstanding (diluted)
1.56B+23.2%Operating Expenses
$8.86BCash & Debt
$8.15BReturn of Capital
$1.75BRevenue by Segment (annual)
$58.74BDividend per Share
$1.06Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $58.74B | $10.26B | $6.60 |
| 2024 | $54.07B | $7.04B | $4.54 |
| 2023 | $45.81B | $5.96B | $3.81 |
| 2022 | $44.35B | $3.29B | $2.12 |
| 2021 | $37.42B | $112.00M | $0.08 |
| 2020 | $26.62B | $3.20B | $2.44 |
| 2019 | $24.38B | $1.33B | $1.03 |
| 2018 | $22.09B | $2.15B | $1.70 |
| 2017 | $22.46B | $3.00B | $2.37 |
| 2016 | $23.00B | $3.50B | $2.77 |
| 2015 | $24.71B | $2.83B | $2.23 |
| 2014 | $26.55B | $1.23B | $0.98 |
| 2013 | $25.81B | $2.56B | $2.04 |
| 2012 | $27.97B | $6.24B | $4.99 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from AZN's reported EPS growth of 2.2% a year over 13 years.
- EPS in 5 years
- $7.38
- Implied price
- $199.17
- Return from $174.35
- 2.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $99.02 — -43.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 19 | 23 | 27 | 31 | 35 |
|---|---|---|---|---|---|
| -7.8% | -13.6% | -10.3% | -7.4% | -4.8% | -2.4% |
| -2.8% | -9.0% | -5.4% | -2.3% | 0.4% | 2.9% |
| 2.2% | -4.3% | -0.5% | 2.7% | 5.6% | 8.2% |
| 7.2% | 0.4% | 4.3% | 7.7% | 10.7% | 13.5% |
| 12.2% | 5.1% | 9.2% | 12.7% | 15.9% | 18.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
30-40.00%Social Signal Score
Mentions (100)
- Newsdefenseworld.net·1d ago·Negative
90,534 Shares of AstraZeneca Plc $AZN Acquired by Advisors Asset Management Inc. Advisors Asset Management Inc. bought a new position in AstraZeneca Plc (NYSE: AZN) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 90,534 shares of the company's stock, valued at approximately $14,619,000. Several other institutional investors and hedge funds have also recently modified their
View source ↗ - Newszacks.com·5d ago·Neutral
AstraZeneca Stock Up 12% in a Month: Time to Buy, Sell or Hold? AZN's 16 blockbuster drugs, strong oncology sales and pipeline opportunities support its $80B revenue target, despite generic pressure and clinical setbacks.
View source ↗ - Newszacks.com·6d ago·Negative
AstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug Klygefa AZN secures US and EU approval for Klygefa, a once-weekly gMG treatment that offers patients greater convenience.
View source ↗ - Newsbarrons.com·6d ago·Negative
Summit's FDA Setback Is a Reality Check for Next-Gen Cancer Drugs Summit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.
View source ↗ - Newsbusinesswire.com·9d ago·Negative
Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's IMFINZI® (durvalumab) in combination with enfortumab vedotin-ejfv (EV) as neoadjuvant treatment, followed by IMFINZI monotherapy as adjuvant treatment after radical cystectomy (surgery to remove the bladder), has been approved in the US for the treatment of adult patients with muscle-in
View source ↗ - Newsreuters.com·9d ago·Neutral
AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports
View source ↗ - Newsreuters.com·9d ago·Negative
EU panel backs AstraZeneca hypertension drug baxdrostat EU panel backs AstraZeneca hypertension drug baxdrostat
View source ↗ - Newsseekingalpha.com·11d ago·Neutral
…cline AstraZeneca's specialty medicines in Oncology, Respiratory, and Rare Diseases are driving double-digit growth, offsetting patent cliff impacts in legacy drugs. AZN trades at a significant valuation discount: a non-GAAP FWD P/E of 18.46x and a PEG of 1.28, below sector medians, supporting a BUY rating. Q3 FY2026 saw 7% revenue growth and 4 percentage point core margin expansion, with strong pipeline momentum and 12 positive Phase III readouts.
View source ↗ - Newsbusinesswire.com·12d ago·Neutral
AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced $1.6 million in grants to nonprofit organizations across the US through its Accelerate Change Together (ACT) on Health Equity initiative. The initiative supports programs that prioritize the social, cultural and linguistic needs of communities that have experienced barriers to care and opportunity. Through the 6th annual Community
View source ↗ - Newsdefenseworld.net·16d ago·Positive
AstraZeneca Plc (NYSE:AZN) Stock Has Average Price Target of $206.67 According to Brokerages AstraZeneca Plc (NYSE: AZN - Get Free Report) has received a consensus rating of "Moderate Buy" from the nineteen ratings firms that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and sixteen have given a buy recommendation to the company. The average 1 year price target
View source ↗ - Newsfool.com·21d ago·Positive
AstraZeneca: 3 Key Takeaways for Long-Term Investors Total revenue grew 7% across the first nine months of 2026. AstraZeneca launched a $2 billion restructuring initiative through 2029.
View source ↗ - Newsseekingalpha.com·22d ago·Positive
AstraZeneca PLC (AZN) Q3 2026 Earnings Call Transcript AstraZeneca PLC (AZN) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·23d ago·Negative
AstraZeneca Q3 Earnings Call Highlights AstraZeneca NYSE: AZN reported continued revenue and earnings growth for the first nine months of 2026, supported by double-digit expansion in oncology, rare disease and respiratory and immunology, while loss-of-exclusivity pressures weighed on parts of its cardiovascular, renal and metabolism portfolio.
View source ↗ - Newszacks.com·23d ago·Neutral
AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth AstraZeneca beats Q3 earnings and revenue estimates as oncology sales surge 17%, offsetting generic pressure on mature drugs.
View source ↗ - Newsbarrons.com·23d ago·Neutral
AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling Stock AstraZeneca aims to free up funds to reinvest into its pipeline and meet its goal of $80 billion in annual revenue by 2030.
View source ↗ - Newsreuters.com·23d ago·Positive
FTSE 100 set for monthly gains; AstraZeneca up after results London's FTSE 100 looked on track to log its first monthly gain in three months, edging up on Friday as AstraZeneca rose, with investors welcoming a budget that was softer than expected on taxes.
View source ↗ - Newswsj.com·23d ago·Negative
AstraZeneca Posts Revenue, Profit Growth on Strong Cancer-Drug Sales The U.K. drugmaker reported net profit of $3.12 billion for the third quarter, up from $2.535 billion for the same period last year.
View source ↗ - Newsbusinesswire.com·26d ago·Neutral
Breast Cancer Canada and AstraZeneca Canada Advance Next-Generation Survivorship Research TORONTO--(BUSINESS WIRE)--Breast Cancer Canada and AstraZeneca Canada are investing $200,000 in matched research funding to address critical gaps in breast cancer survivorship and improve care for Canadians living with and beyond the disease. Announced at Breast Cancer Canada's Canadian Night reception during the European Society for Medical Oncology (ESMO) Congress in Madrid, the funding will support two C
View source ↗ - Newsmarketbeat.com·27d ago·Neutral
AstraZeneca Highlights Breakthrough Cancer Data at ESMO 2026 Investor Update Astrazeneca NYSE: AZN highlighted new clinical data across bladder, lung and gastric cancers at its ESMO 2026 investor event, including four presidential presentations that executives said support the company's oncology growth strategy.
View source ↗ - News247wallst.com·27d ago·Neutral
Is AstraZeneca's Pipeline Fuel Enough to Spark a Post-Earnings Breakout on Oct. 30? AstraZeneca (NYSE:AZN | AZN Price Prediction) reports third-quarter results on Friday, October 30. Farxiga generics are cutting into sales, and a major cardiology trial has failed.
View source ↗ - Newsseekingalpha.com·27d ago·Neutral
Baron Health Care Fund: Q3 2026 New Positions And Exits During the quarter, we added 4 new positions and exited 14, bringing the number of positions in the Fund to 33. We initiated a position in Biogen Inc., a company that we believe is in the early stages of a transformation. We sold Madrigal Pharmaceuticals, Inc. to manage risk ahead of a competitor's clinical trial readout.
View source ↗ - Newsseekingalpha.com·27d ago·Neutral
Baron Health Care Fund Q3 2026 Top Contributors And Detractors TMO's organic growth of 5% exceeded consensus by 200 basis points, and management raised full-year organic growth guidance/. MTD's local-currency sales grew 6%, exceeding prior guidance of 3%. TEVA management raised guidance for all three brands.
View source ↗ - Newswsj.com·28d ago·Negative
AstraZeneca Readies New Portfolio of Targeted Cancer Therapies AstraZeneca is readying to file the first of a new portfolio of targeted cancer drugs for regulatory approval, moving to cement its position in one of the fastest-growing corners of the oncology market.
View source ↗ - Newsbusinesswire.com·28d ago·Neutral
TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-bas
View source ↗ - Newsseekingalpha.com·30d ago·Positive
AstraZeneca: This Mighty Pharma Is Undervalued Ahead Of Q3 Earnings AstraZeneca remains a long-term Buy despite recent setbacks, underpinned by robust product and pipeline strength. AZN targets $80bn in revenues by 2030, supported by 14 current blockbusters and a pipeline potentially adding 12 more by the decade's end. Recent pipeline wins in oncology, respiratory, and immunology offset the eplontersen ATTR-CM study failure and Farxiga's US LOE.
View source ↗ - Newszacks.com·31d ago·Negative
AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy AZN wins accelerated FDA approval for Ultomiris in IgA nephropathy, marking the fifth approved indication for the drug in the United States.
View source ↗ - Newsreuters.com·32d ago·Negative
AstraZeneca says FDA approves drug for rare kidney disease in adults AstraZeneca says FDA approves drug for rare kidney disease in adults
View source ↗ - Newsbenzinga.com·33d ago·Negative
AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study AstraZeneca Plc (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) on Tuesday shared full results from the Phase 3 CROSSING trial of Tezspire (tezepelumab) in adolescents and adults with uncontrolled eosinophilic esophagitis (EoE).
View source ↗ - Newsproactiveinvestors.com·33d ago·Negative
Jefferies puts AstraZeneca kidney drug trial success odds at 59% Jefferies, the investment bank, estimates a 59% probability that AstraZeneca PLC (LSE:AZN, NYSE:AZN)'s zibotentan succeeds in the phase 3 ZENITH-HP kidney disease trial, which is due to report in the first half of 2027. The broker rates AstraZeneca, the FTSE 100 drugmaker, a 'buy' with a price target of 17,500p, which implies 41% upside from Monday's close of 12,446p.
View source ↗ - Newsreuters.com·33d ago·Negative
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
View source ↗ - Newswsj.com·33d ago·Neutral
AstraZeneca Partners With Oracle to Refine Clinical Research With AI AstraZeneca is teaming up with Oracle to refine clinical research, in the latest artificial-intelligence partnership in the pharmaceutical industry.
View source ↗ - Newszacks.com·37d ago·Negative
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month AZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.
View source ↗ - Newszacks.com·38d ago·Neutral
Astrazeneca (AZN) Rises Higher Than Market: Key Facts Astrazeneca (AZN) closed the most recent trading day at $166.68, moving +2.87% from the previous trading session.
View source ↗ - Newsproactiveinvestors.com·38d ago·Positive
RBC keeps AstraZeneca at ‘outperform' ahead of AVANZAR lung cancer trial RBC Capital Markets has maintained its 'outperform' rating on AstraZeneca PLC (LSE:AZN, NYSE:AZN), the FTSE 100 pharmaceutical group, with a 14,500p target price, expecting a quiet third quarter before results on Friday 30 October. It forecasts third-quarter revenue of $16.3 billion, 1.8% above the consensus estimate of $16.0 billion, and core earnings per share (EPS) of $2.61, 0.8% ahead of the $2.59 consensus.
View source ↗ - Newsseekingalpha.com·41d ago·Positive
AstraZeneca PLC (AZN) Presents at American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting Transcript AstraZeneca PLC (AZN) Presents at American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting Transcript
View source ↗ - Newsmarketbeat.com·41d ago·Negative
AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint Astrazeneca NYSE: AZN presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for hypophosphatasia (HPP), at the American Society for Bone and Mineral Research annual meeting in Boston. The company said the therapy showed improvements in several measures of function, pain and fatigue in adolescents and adults, although the HICKORY trial did not meet its primary endpoint.
View source ↗ - Newsproactiveinvestors.com·41d ago·Negative
AstraZeneca's efzimfotase alfa adult data point to $4.4bn peak sales potential, says Citi Citi has maintained its 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) with a target price of £186, arguing that detailed trial data for its rare disease drug efzimfotase alfa support a peak sales scenario almost double its current base case if the therapy secures broad adult approval in the US. The data, presented at the American Society for Bone and Mineral Research meeting, came from the Phase III…
View source ↗ - Newsbusinesswire.com·45d ago·Neutral
Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Guardant360® CDx has received CE-marking under Europe's in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic (CDx) to identify patients with estrogen receptor (ER)-positive, HER2-n
View source ↗ - Newsproactiveinvestors.com·46d ago·Positive
Jefferies maintains 'buy' rating on AstraZeneca ahead of third-quarter results Jefferies maintained a 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the biopharmaceutical company, with a 17,500p price target, representing 46% potential upside from its 11,958p share price. The broker expects AstraZeneca to report third-quarter revenue about 1% ahead of the Visible Alpha consensus and core earnings before interest and tax at 3% above expectations.
View source ↗ - Newszacks.com·47d ago·Neutral
Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider In the latest trading session, Astrazeneca (AZN) closed at $158.61, marking a +1.33% move from the previous day.
View source ↗ - Newsproactiveinvestors.com·47d ago·Positive
Citi raises AstraZeneca target to £186 as tozorakimab prospects improve Citi raised its target price for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, to £186 from £178 and retained its 'buy' rating after recent clinical developments. The broker increased its peak sales forecast for tozorakimab to $7 billion and for SERENA-6 to $1.1 billion, more than offsetting the removal of its $1.7 billion forecast for SERENA-4.
View source ↗ - Newscnbc.com·48d ago·Negative
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment AstraZeneca CEO Pascal Soriot told CNBC that Summit Therapeutics' lead drug could help power next-generation cancer combinations that could be the "future of cancer care." Soriot spoke exclusively with CNBC from the site of AstraZeneca's new more than $1 billion research and development facility in Kendall Square in Cambridge, Massachusetts.
View source ↗ - Newsreuters.com·51d ago·Negative
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination AstraZeneca and Daiichi Sankyo have entered into a clinical collaboration with Summit Therapeutics to test their cancer drug, Datroway, in combination with Summit's ivonescimab across multiple tumour types, including lung and breast cancers.
View source ↗ - Newsbusinesswire.com·51d ago·Negative
…IRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) to evaluate ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in combination with Datroway® (datopotamab deruxtecan), a TROP2-directed antibody drug conjugate (ADC), across multiple solid tumor settings, intending to include breast and lung cancer. The companies i.
View source ↗ - Newsbusinesswire.com·51d ago·Neutral
…s to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (Nasdaq: SMMT) to evaluate Datroway® (datopotamab deruxtecan) in combination with ivonescimab across multiple tumor types including lung and breast cancers. The companies intend to begin with a phase 3 trial in first-line triple negative br…
View source ↗ - News247wallst.com·53d ago·Neutral
AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant read ivonescimab correctly.
View source ↗ - Newszacks.com·54d ago·Neutral
Astrazeneca (AZN) Registers a Bigger Fall Than the Market: Important Facts to Note Astrazeneca (AZN) closed at $164.21 in the latest trading session, marking a -1.17% move from the prior day.
View source ↗ - Newszacks.com·54d ago·Neutral
Summit Shares Jump on $2B Strategic Investment From AstraZeneca SMMT shares jump as AstraZeneca commits $2 billion to accelerate ivonescimab development and expand clinical collaboration.
View source ↗ - Newsproactiveinvestors.com·54d ago·Negative
AstraZeneca's $2 billion Summit stake wins backing from UBS and Jefferies AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, has won positive responses from UBS and Jefferies after investing $2 billion in Summit Therapeutics and agreeing a cancer drug collaboration. UBS said the investment gives AstraZeneca exposure to the programmed death-1 and vascular endothelial growth factor (PD-1/VEGF) class, which combines immune-system activation with inhibition of tumour blood …
View source ↗ - Newsinvezz.com·54d ago·Neutral
Summit Therapeutics jumps 20% after AstraZeneca's $2 billion bet: what it signals Summit Therapeutics shares surged more than 20% in pre-market trading on Tuesday after AstraZeneca agreed to invest $2 billion in the company and collaborate on a series of clinical studies involving their cancer treatments. The deal, announced late Monday, sent UK-listed shares of AstraZeneca 1.9% higher to a two-month high.
View source ↗ - Newsreuters.com·54d ago·Negative
Summit soars after $2 billion investment from AstraZeneca for cancer therapies Summit Therapeutics' shares rose 23% in premarket trading on Tuesday after the drugmaker said AstraZeneca would invest $2 billion in the company to test cancer treatments together.
View source ↗ - Newsproactiveinvestors.com·54d ago·Negative
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, will invest $2 billion in Summit Therapeutics Inc. as part of a wider cancer drug collaboration.
View source ↗ - Newstheguardian.com·54d ago·Negative
Anthropic warns of ‘existential risks to humanity' from AI; AstraZeneca makes $2bn cancer drug tie-up – business live Rolling coverage of the latest economic and financial news
View source ↗ - Newsreuters.com·55d ago·Negative
AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination HUTCHMED (China) said on Tuesday Anglo-Swedish drugmaker AstraZeneca had filed an application with the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination in patients with advanced lung cancer.
View source ↗ - Newswsj.com·55d ago·Negative
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs Summit shares surged in after-hours trading following the news of AstraZeneca's investment, as the two companies plan to ramp up their collaboration on developing cancer treatments.
View source ↗ - Newsreuters.com·55d ago·Negative
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up Summit Therapeutics said on Monday that British drugmaker AstraZeneca would invest $2 billion in the company and collaborate on a series of studies testing their cancer treatments together.
View source ↗ - Newsbusinesswire.com·55d ago·Neutral
…ing its goal of making a significant difference in the lives of patients with cancer. Specifically, Summit has established agreements with AstraZeneca (LSE/STO/NYSE: AZN) for a strategic equity investment in Summit and a clinical collaboration focused on ivonescimab and sonesitatug vedotin (sone-ve). Moreover, Summit and AstraZeneca intend to evaluat.
View source ↗ - Newsbusinesswire.com·55d ago·Neutral
Eccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004) BOSTON & SHANGHAI--(BUSINESS WIRE)--Eccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004).
View source ↗ - Newszacks.com·55d ago·Negative
Is AstraZeneca's Oncology Portfolio Positioned for Continued Growth? AZN's oncology sales rise 15% in H1 2026 as newer drugs, label expansions and a deep pipeline support continued franchise growth.
View source ↗ - Newsseekingalpha.com·58d ago·Positive
…veraging mid-single-digit revenue growth into robust EPS gains, driven by oncology and pipeline execution. Recent EU approval of Trixeo Aerosphere for asthma expands AZN's addressable market, reinforcing its Respiratory & Immunology franchise with durable, long-cycle growth potential. AZN's pipeline momentum—six positive Phase III readouts and 30 approvals—underpins its long-term growth narrative despite isolated late-stage failures.
View source ↗ - Newsbusinesswire.com·58d ago·Negative
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) in combination with enfortumab vedotin (EV) has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or have declined cisplat
View source ↗ - Newszacks.com·60d ago·Negative
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.
View source ↗ - Newszacks.com·60d ago·Neutral
AstraZeneca's Trixeo Secures Approval for Asthma in the EU AZN's Trixeo wins EU approval for asthma, adding an indication backed by phase III data showing improved lung function.
View source ↗ - Newszacks.com·62d ago·Neutral
Astrazeneca (AZN) Ascends But Remains Behind Market: Some Facts to Note In the latest trading session, Astrazeneca (AZN) closed at $168.1, marking a +1.22% move from the previous day.
View source ↗ - Newszacks.com·62d ago·Neutral
AZN's Klygefa Gets CHMP Nod for Generalised Myasthenia Gravis in EU AstraZeneca's Klygefa wins a positive EU recommendation for AChR-positive gMG, backed by phase III data and a convenient once-weekly treatment option.
View source ↗ - Newszacks.com·62d ago·Neutral
AZN vs. MRK: Comparing Keytruda, Pipelines and Growth Strategies AZN and MRK bring distinct oncology strengths, growth plans, pipeline opportunities and patent-related challenges to the table.
View source ↗ - Newszacks.com·65d ago·Negative
FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug AstraZeneca wins FDA priority review for efzimfotase alfa, potentially expanding its HPP treatment opportunity with less frequent dosing.
View source ↗ - Newsreuters.com·66d ago·Negative
AstraZeneca-Daiichi breast cancer drug cleared for NHS use in England AstraZeneca and Daiichi Sankyo said on Thursday their breast cancer treatment Enhertu has been approved for use in England's state-run healthcare system, expanding access to a drug that has been available in Scotland since 2023.
View source ↗ - Newszacks.com·67d ago·Positive
Is It Worth Investing in Astrazeneca (AZN) Based on Wall Street's Bullish Views? The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
View source ↗ - Newszacks.com·69d ago·Neutral
Why the Market Dipped But Astrazeneca (AZN) Gained Today In the latest trading session, Astrazeneca (AZN) closed at $163.78, marking a +2.25% move from the previous day.
View source ↗ - Newszacks.com·69d ago·Neutral
AZN's Etcamah Fails Late-Stage Study for First-line Breast Cancer AstraZeneca's Etcamah fails to improve PFS significantly in a phase III first-line breast cancer study, while its approved use remains unaffected.
View source ↗ - Newswsj.com·69d ago·Negative
AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial The Etcamah results came a week after the U.S. granted approval for the drug for advanced breast cancer upon the detection of a specific mutation.
View source ↗ - Newsmarketbeat.com·70d ago·Negative
AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears Astrazeneca NYSE: AZN presented Phase III data for tozorakimab in chronic obstructive pulmonary disease, or COPD, at the 2026 European Respiratory Society Congress in Barcelona, reporting statistically significant reductions in moderate-to-severe exacerbations across two trials and across a broad range of patient subgroups.
View source ↗ - Newsseekingalpha.com·71d ago·Negative
AstraZeneca: The $5 Billion Pipeline Hole Did Not Stay Open Long Wainua's July failure erased more than $30 billion of AstraZeneca's market value and raised questions about a pipeline investors had learned to trust. The full tozorakimab results are more interesting than the earlier headline. COPD attacks fell by 29% to 34% in two large Phase III trials. A 23% reduction among patients with low eosinophil counts could open a part of the COPD market that existing biologics do not serve well.
View source ↗ - Newsinvestors.com·72d ago·Positive
AstraZeneca Stock Trips On Unexpected Failure In Breast Cancer AstraZeneca stock toppled in late trades Friday after the company's experimental breast cancer treatment failed to pass muster.
View source ↗ - Newsreuters.com·72d ago·Negative
Astrazeneca's breast cancer drug fails late-stage trial AstraZeneca said on Friday its breast cancer drug failed to meet the main goal of improving progression-free survival during a late-stage trial.
View source ↗ - Newsproactiveinvestors.co.uk·73d ago·Negative
AstraZeneca's $5bn drug promise is no 'buy' signal for Deutsche AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drew praise from Deutsche Bank for tozorakimab's lung disease data, but the broker paired its positive assessment with a bearish verdict on the shares. The shares traded at 11,634p, broadly flat, while the bank rated the drugmaker 'sell' with a target price of 11,500 pence.
View source ↗ - Newsproactiveinvestors.co.uk·74d ago·Positive
AstraZeneca COPD data back Citi's $7b peak sales case AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drew Citi's backing after tozorakimab trial results, supporting an upside case of at least $7 billion in peak sales, roughly twice consensus. Behind the bullish call, phase III data presented at the European Respiratory Society meeting showed tozorakimab reduced flare-ups in chronic obstructive pulmonary disease (COPD).
View source ↗ - Newsreuters.com·74d ago·Negative
AstraZeneca drug reduces lung disease flare-ups in late-stage trials Today we feature data from studies being presented at the ongoing European Respiratory Society Congress in Barcelona.
View source ↗ - Newsseekingalpha.com·75d ago·Positive
AstraZeneca PLC (AZN) Presents at European Respiratory Society (ERS) Congress Transcript AstraZeneca PLC (AZN) Presents at European Respiratory Society (ERS) Congress Transcript
View source ↗ - Newswsj.com·75d ago·Negative
AstraZeneca Says Lung-Disease Drug Shows Benefits Across Patient Groups AstraZeneca said its new drug for COPD showed benefits across a broad patient population in late-stage clinical trials, boosting a medicine the company expects to generate multibillion-dollar sales.
View source ↗ - Newsreuters.com·75d ago·Negative
AstraZeneca's cancer drug combo hits main survival goal in late-stage trial AstraZeneca said on Tuesday its cancer drug Imfinzi combined with Amgen's targeted immunotherapy Imdelltra significantly improved overall survival in first-line extensive-stage small cell lung cancer in a late-stage trial.
View source ↗ - Newscnbc.com·75d ago·Negative
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes AstraZeneca released full results from two successful late-stage trials on its experimental drug for chronic obstructive pulmonary disease. The detailed data reinforces hopes that the product could be a breakthrough treatment for COPD and reach AstraZeneca's peak annual sales forecast of more than $5 billion for the drug.
View source ↗ - Newsproactiveinvestors.co.uk·76d ago·Negative
Citi backs AstraZeneca sentiment boost after Etcamah wins accelerated FDA approval Citi has flagged AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) accelerated approval for Etcamah, known chemically as camizestrant, as a meaningful sentiment driver for the shares. The oral selective oestrogen receptor degrader has been cleared by the US Food and Drug Administration in combination with a CDK4/6 inhibitor for hormone receptor positive, HER2 negative metastatic breast cancer.
View source ↗ - Newszacks.com·76d ago·Neutral
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah AZN's Etcamah wins accelerated FDA approval for certain advanced breast cancer patients, backed by a 56% risk reduction in progression or death.
View source ↗ - Newsbusinesswire.com·79d ago·Negative
Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced Breast Cancer PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) to identify patients with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast c
View source ↗ - Newszacks.com·81d ago·Negative
AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks AstraZeneca's pipeline setbacks weigh on the stock, but blockbuster drugs, oncology growth and a strong launch pipeline offer reasons to stay invested.
View source ↗ - Newszacks.com·81d ago·Positive
AZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets Goal AstraZeneca reports positive SANOVO data, showing Tagrisso plus Orpathys improved PFS in first-line EGFR-mutated NSCLC.
View source ↗ - Newsreuters.com·82d ago·Negative
AstraZeneca lung cancer therapy combination shows promise in advanced study AstraZeneca said on Tuesday that a Chinese late-stage trial of a combination of its cancer drugs Tagrisso and Orpathys significantly improved progression-free survival when given as a first-line treatment for a type of lung cancer.
View source ↗ - Newszacks.com·87d ago·Neutral
AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study AstraZeneca's Tezspire delivers positive CROSSING data in EoE, meeting all primary and secondary endpoints and supporting its expansion potential.
View source ↗ - Newszacks.com·87d ago·Neutral
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
View source ↗ - Newsproactiveinvestors.co.uk·87d ago·Negative
AstraZeneca drug succeeds in trial for swallowing disorder AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) said its drug Tezspire worked in a late-stage trial of patients with eosinophilic esophagitis, a chronic condition that inflames the gullet and makes swallowing difficult. The drug, developed with the American biotech company Amgen, hit both of its main goals and every important secondary one.
View source ↗ - Newsreuters.com·87d ago·Negative
AstraZeneca's asthma drug Tezspire meets all goals in late-stage esophagitis trial AstraZeneca said on Thursday its asthma drug, Tezspire, developed with Amgen , met its main and secondary goals in a late-stage trial for treating eosinophilic esophagitis, a chronic inflammatory disorder of the esophagus.
View source ↗ - Newsproactiveinvestors.co.uk·89d ago·Neutral
AstraZeneca prices €2.55bn euro bond sale across four tranches AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharma group, has priced a €2.55 billion bond offering, tapping the euro debt market for general corporate purposes. The notes were issued on Monday by AstraZeneca Finance LLC, a wholly owned US subsidiary, and carry a full and unconditional guarantee from the parent company.
View source ↗ - Newszacks.com·95d ago·Positive
BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment BMRN's $490M Alesta deal adds ALE1, a potential oral HPP therapy, broadening its rare bone disease portfolio and clinical pipeline.
View source ↗ - Newsseekingalpha.com·95d ago·Negative
AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors? Rumors of an AstraZeneca PLC-Bristol-Myers Squibb Company merger are cooling, yet each company's standalone strength deserves closer scrutiny. Overall, AZN and BMY occupy leading positions in the cancer and immune-mediated inflammatory diseases markets. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the rival.
View source ↗ - Newszacks.com·96d ago·Neutral
AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success AstraZeneca halts a phase III NSCLC study for volrustomig after data show that the regimen is unlikely to meet key survival goals, while other lung cancer trials shine.
View source ↗ - Newsproactiveinvestors.co.uk·96d ago·Positive
AstraZeneca maintains Citi 'buy' rating despite mixed pipeline updates AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has retained a 'buy' rating from Citi following a mixed set of pipeline updates, with the broker saying its underlying investment thesis remains unchanged and that the drugmaker continues to offer the strongest growth and pipeline profile in the sector. Citi highlighted positive results from the Phase III SAFFRON trial, where Tagrisso plus Orpathys met the primary endpoint and demonstrate…
View source ↗ - Newsbenzinga.com·97d ago·Negative
AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies AstraZeneca Plc (NYSE:AZN) on Monday reported a mix of clinical trial outcomes for its lung cancer treatments, achieving notable successes in two late-stage trials while discontinuing a third study due to missed primary endpoints.
View source ↗ - Newsproactiveinvestors.co.uk·97d ago·Neutral
AstraZeneca lung cancer drug combination extends survival in trial AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has reported positive results from a late-stage trial of a two-drug combination for a hard-to-treat form of lung cancer, potentially opening the way to approval around the world. The study tested the company's established lung cancer pill Tagrisso alongside a newer drug called Orpathys, developed with the Hong Kong-based biotech HUTCHMED.
View source ↗
Earnings
Tue, Feb 9(in 3 months)
Consensus estimate $2.32 per share
Typical surprise +4.4% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Oct 30$2.79 vs $2.60beat
- Mon, Jul 27$2.63 vs $2.50beat
- Wed, Apr 29$2.58 vs $2.57beat
- Tue, Feb 10$2.12 vs $2.09beat
- Thu, Nov 6$2.38 vs $2.28beat
- Tue, Jul 29$2.18 vs $2.18beat
Estimates and results for AZN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AZN officers and directors.
- Bought
- $3k
- Sold
- $2.2m
1 trade
1 trade
- Sharma Manibought
- Sharma Manisold
12 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Alan Armstrongsenate · disclosed Jul 21, 2026 (112d later)Buy$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (113d later)Buy$15,001 - $50,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (36d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jan 12, 2026 (25d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Dec 15, 2025 (26d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (24d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Nov 18, 2025 (28d later)Buy$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Oct 10, 2025 (17d later)Sell$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Sep 12, 2025 (318d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (65d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (22d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (57d later)Sell$1,001 - $15,000
- Bruce Westermanhouse · AR04 · disclosed May 13, 2025 (22d later)Sell$1,001 - $15,000
- Bruce Westermanhouse · AR04 · disclosed Apr 17, 2025 (45d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (26d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Sep 20, 2023 (37d later)Sell$100,001 - $250,000
- Michael T. McCaulhouse · TX10 · disclosed Sep 20, 2023 (37d later)Sell$50,001 - $100,000
- Ro Khannahouse · CA17 · disclosed Sep 6, 2023 (26d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
